- Coloplast’s third-quarter revenue was DKK 6.96 billion, falling short of the DKK 7.06 billion estimate.
- EBITDA came in at DKK 2.26 billion, slightly below the expected DKK 2.27 billion.
- The EBIT for the quarter was reported at DKK 1.83 billion.
- Net income was DKK 805 million, which missed the estimate of DKK 944.6 million.
- A new Chronic Care Commercial business unit is being established effective immediately.
- The company reported a 7% organic growth and an EBIT margin of 28%, aligning with their financial guidance for 2024/25.
- Growth was broad-based across chronic care businesses but challenged by issues in China.
- Market consensus shows 8 buy ratings, 16 hold ratings, and 2 sell ratings for Coloplast.
“`
Coloplast A/S on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely following Coloplast A/S, a leading player in medical devices and solutions. Baptista Research‘s report, titled “COLOPLAST – Why Recent Acquisitions Could Be the Catalyst for Explosive Growth!“, highlights the company’s strategic adjustments amidst their first half 2024-2025 results. The report mentions a significant leadership shift, with Lars Rasmussen stepping in as Interim CEO after Kristian Villumsen’s departure, signaling a renewed focus on decisiveness and execution efficiency in the face of organic growth challenges.
A look at Coloplast A/S Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Coloplast A/S, a company focused on developing healthcare products, has received a mixed outlook based on the Smartkarma Smart Scores. With a strong dividend score of 4, investors can potentially benefit from consistent income streams. However, the value score of 2 indicates that the stock may not be considered undervalued at the moment. In terms of growth and resilience, Coloplast A/S received scores of 3, showing moderate prospects in these areas. The momentum score of 2 suggests that the stock may not be experiencing significant upward price movement in the short term.
Despite the varied scores, Coloplast A/S remains a reputable company that manufactures a range of healthcare products for different needs such as ostomy, incontinence, mastectomy, wound healing, and skin care. The company’s commitment to research in collaboration with healthcare professionals and user groups highlights its dedication to product innovation and quality. With a global reach, Coloplast A/S continues to serve health care professionals, dealers, and product users worldwide.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
